Viatris/$VTRS
1D1W1MYTD1Y5YMAX
Capital at risk
About Viatris
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
- Ticker
- $VTRS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 30,000
- Headquarters
- Canonsburg, United States
- Website
- www.viatris.com
Viatris Metrics
BasicAdvanced
$19B
-
-$0.35
0.89
$0.48
2.91%
Price and volume
Market cap
$19B
Beta
0.89
52-week high
$18.39
52-week low
$9.43
Average daily volume
9.4M
Dividend rate
$0.48
Financial strength
Current ratio
1.585
Quick ratio
0.632
Long term debt to equity
0.814
Total debt to equity
0.955
Interest coverage (TTM)
3.08%
Profitability
EBITDA (TTM)
4,292.5
Gross margin (TTM)
40.31%
Net profit margin (TTM)
-2.79%
Operating margin (TTM)
10.64%
Effective tax rate (TTM)
37.98%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
2.67%
Return on equity (TTM)
-2.75%
Valuation
Price to revenue (TTM)
1.298
Price to book
1.34
Price to tangible book (TTM)
-3.14
Price to free cash flow (TTM)
10.56
Free cash flow yield (TTM)
9.47%
Free cash flow per share (TTM)
1.564
Dividend yield (TTM)
2.91%
Forward dividend yield
2.91%
Growth
Revenue change (TTM)
4.40%
Earnings per share change (TTM)
-87.86%
3-year revenue growth (CAGR)
-1.88%
10-year revenue growth (CAGR)
4.02%
3-year earnings per share growth (CAGR)
-38.64%
10-year earnings per share growth (CAGR)
-13.88%
What the Analysts think about Viatris
Analyst ratings (Buy, Hold, Sell) for Viatris stock.
Analyst projections of the future price of Viatris stock.
Bulls say / Bears say
Viatris raised its 2026 guidance midpoints across revenue, adjusted EBITDA, adjusted EPS and free cash flow after Q2, signaling better-than-expected operating momentum. (Viatris Q2 2026 results)
Q2 2026 showed solid operating improvement: revenue increased 5% reported, adjusted EPS rose 11%, adjusted EBITDA grew 10%, and gross leverage fell to 2.9x; the company also returned approximately $550 million to shareholders. (Viatris Q2 2026 results)
The pipeline is producing tangible catalysts: Viatris received FDA approval for the once-weekly Gwyn Lo contraceptive patch, reported positive Phase 3 VR-205 results in Japanese IgA nephropathy, and received FDA acceptance for its fast-acting meloxicam NDA. (Gwyn Lo approval, VR-205 results, Meloxicam NDA)
Growth remains uneven geographically: in Q2 2026, operational sales declined 2% in Emerging Markets and were flat in JANZ, while growth was heavily concentrated in Greater China. This raises exposure to regional demand, pricing and execution volatility. (Viatris Q2 2026 results)
Reported earnings quality remains a concern: Viatris posted a $118.8 million GAAP net loss in Q2, while adjusted free cash flow excluded $120 million of transaction-related and restructuring costs; full-year guidance also excludes such costs. (Viatris Q2 2026 results)
The May 2026 departure of CFO Doretta Mistras and appointment of an interim successor create execution and governance risk while Viatris pursues a permanent replacement. (Viatris CFO transition)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Viatris Financial Performance
Revenues and expenses
Viatris Earnings Performance
Company profitability
Upcoming events
Viatris News
AllArticlesVideos
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Proactive Investors3 weeks ago
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Benzinga1 month ago
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
CNBC2 months ago
Funds containing Viatris
AllUSDGBPEUR
Fund name | Fund size | $VTRS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.46% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.46% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.34% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.30% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.30% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.